Navigation Links
Pelosi: Budget is a Blueprint for the Future
Date:4/29/2009

t was passed early on in the recovery package, known as the stimulus package -- it's called 'Greener Stimulus.' Signed in February, the stimulus package is chalk full of clean-tech goodies with $43 billion dollars in grants for clean power, extensions of tax credits for solar wind, geothermal and energy efficiency programs, smart-grid funding, weatherization programs, and a new tax credit for clean-tech hardware manufacturing.

"I mention that because we must see that this budget in the context of the issues in which we are trying to advance. Of themselves, they are worthy. They have their justification -- as I mentioned in the case of energy -- but they are also investments that will grow our economy and create jobs.

"When it comes to health care -- another pillar of the Obama budget. As the President says, health care reform is entitlement reform. As we go forward with universal quality, accessible health care for all Americans -- which this budget will lead us to -- we'll be reducing the cost of health care for the American people and in lowering those costs we will lower the costs to our budget and cost to the deficit of Medicare and Medicaid.

"This is not just about the personal health of the American people -- that would be justification enough -- the personal well-being of our country. And it's not only about health care; it's about the health of the American people. It's about prevention. It's about diet, not diabetes.

"So we are moving in a path that lowers costs, makes America healthier. And in doing so, as I say, it will not only help individuals with their health and personal well-being, but we are helping businesses to compete. Health care costs are a competitiveness issue. And if we're going to compete domestically and internationally, we must lower health care costs for businesses.

"It's about costs to our economy. Of all this money spent on health care, and not ha
'/>"/>

SOURCE Office of the Speaker of the House
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Pelosi: Administration Will Not Force Veterans to Use Private Insurance to Pay for Treatment of Combat-Related Injuries
2. Pope to Pelosi: Catholic Politicians Must Protect Life
3. Pelosi: Today is a Very Special Day for Us in the House; We Are Going to Help 11 Million Children
4. Pelosi: SCHIP Vote Brings Us One Step Closer to Providing Health Care for 11 Million Children
5. Pelosi: America Must Stand Up to Cancer
6. Pelosi: Medicare Vote a Remarkable Testament to the Powerful Voice of Americas Seniors and Their Health Care Providers
7. Pelosi: Genetic Information Nondiscrimination Act Will Protect Americans from Misuse of Genetic Information
8. Pelosi: By Literally Fixing Broken Hearts, Dr. DeBakey Has Given Hope and Health to Millions
9. Pelosi: President Bushs Proposed Medicare and Medicaid Cuts Are Exactly the Wrong Medicine
10. Pelosi: We Will Keep Fighting Next Year to Cover 10 Million Children and Improve Benefits for Low-Income Seniors
11. Pelosi: In 48 Hours, Congress Must Choose Between Meeting the Needs of Americas Children or Not
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 1SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 2SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 3SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 4Studying cancer in pet dogs to find new treatments for human patients 59325 1Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 1Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 4Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 5Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 6Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 7Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 8